1. Safety Signals Using Proportional Reporting Ratios from Company and Regulatory Authority Databases

   • Andrzej Czarnecki
   • Simon Voss

   Pharmacovigilance 30 December 2008 Pages: 205 - 210

2. Pharmacokinetic and Pharmacodynamic Characterization of Non-antiarrhythmic QT-Prolonging Drugs Associated with Torsades de Pointes

   • Yeong-Liang Lin
   • Keith Chan

   QT Prolongation 30 December 2008 Pages: 211 - 219

3. Special Section: Benefit: Risk Evaluation in Clinical Trials

   • Scott Evans

   Benefit: Risk Considerations 30 December 2008 Pages: 221 - 222

4. Measures for Conducting Comparative Benefit: Risk Assessment

   • Christy Chuang-Stein
   • Richard Entsuah
   • Yili Pritchett

   Benefit: Risk Considerations 30 December 2008 Pages: 223 - 233

5. A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More?

   • Robert T. O’Neill

   Benefit: Risk Considerations 30 December 2008 Pages: 235 - 245

6. The GSK Clinical Study Results Database: Site Utilization Metrics for a Large Public Database

   • Craig A. Metz
   • Frank Rockhold
   • Andrew Freeman

   Clinical Trials 30 December 2008 Pages: 247 - 252

7. A Two-Stage Design for Drug Screening Trials Based on Continuous Endpoints

   • Hsiao-Hui Tsou
   • Chin-Fu Hsiao
   • Jen-pei Liu

   Clinical Trials 30 December 2008 Pages: 253 - 262

8. Drug Information Availability and Preferences of Health Care Professionals in Illinois: A Pilot Survey Study

   • Jacob P. Gettig

   Drug Information 30 December 2008 Pages: 263 - 272

9. Bioinformatics Modernization and the Critical Path to Improved Benefit-Risk Assessment of Drugs

   • Armando Oliva
   • Randy Levin
   • Janet Woodcock

   Drug Information 30 December 2008 Pages: 273 - 279

10. Patient Protection and Access to Innovative Medicinal Products in the European Union

    • Markus Hartmann
    • Florence Hartmann-Vareilles

    Drug Information 30 December 2008 Pages: 281 - 295